{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-002410","form_type":"8-K","ticker":"RDGL","cik":"0001449349","company_name":"VIVOS INC","filed_at":"2022-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.522044+00:00","generated_at":"2026-06-27T14:55:12.710366+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vivos 2021 recap: first equine IsoPet therapy, FDA pre-sub for RadioGel IDE, production improved 3x","bullets":["University of Missouri performed first equine IsoPet therapy; excellent outcome confirmed after monitoring.","Pre-submission meeting with FDA for RadioGel IDE; used rapid breakthrough review; revised IDE to be submitted after biocompatibility tests.","Polymer production time reduced and output increased by factor of three; contaminants reduced below FDA guidelines.","New provisional patent filed covering improved hydrogel, other isotopes, and anti-circumvention techniques.","Capital structure in excellent shape: no toxic debt or derivatives; all SEC filings timely."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-002410","json":"https://secwatch.observer/filing/0001493152-22-002410.json","markdown":"https://secwatch.observer/filing/0001493152-22-002410.md","text":"https://secwatch.observer/filing/0001493152-22-002410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1449349/000149315222002410/0001493152-22-002410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1449349/000149315222002410/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T14:55:12.710366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}